Related references
Note: Only part of the references are listed.Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Wang Chun Kwok et al.
LUNG CANCER (2021)
Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience
Kuruswamy Thurai Prasad et al.
CURRENT PROBLEMS IN CANCER (2020)
Cumulative pemetrexed dose increases the risk of nephrotoxicity
N. de Rouw et al.
LUNG CANCER (2020)
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Wang Chun Kwok et al.
JOURNAL OF CHEMOTHERAPY (2020)
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102
Takashi Yokoi et al.
INTERNAL MEDICINE (2019)
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial
Marco Platania et al.
LUNG CANCER (2019)
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo et al.
CANCER RESEARCH AND TREATMENT (2019)
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302
Satoshi Ikeda et al.
ONCOLOGY (2019)
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting
Katherine B. Winfree et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
Suzanne McMullen et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2019)
Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients
Naoyuki Nogami et al.
RESPIRATORY INVESTIGATION (2019)
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
Jyoti D. Patel et al.
CLINICAL LUNG CANCER (2018)
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Gary Middleton et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study
Sabine Visser et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study
Cesare Gridelli et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
G. V. Scagliotti et al.
LUNG CANCER (2014)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2012)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
Jacek Jassem et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
T Brodowicz et al.
LUNG CANCER (2006)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
